Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Non-Current Debt (2022 - 2025)

Tarsus Pharmaceuticals has reported Non-Current Debt over the past 4 years, most recently at $72.4 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $72.4 million for Q4 2025, up 0.83% from a year ago — trailing twelve months through Dec 2025 was $72.4 million (up 0.83% YoY), and the annual figure for FY2025 was $72.4 million, up 0.83%.
  • Non-Current Debt for Q4 2025 was $72.4 million at Tarsus Pharmaceuticals, roughly flat from $72.3 million in the prior quarter.
  • Over the last five years, Non-Current Debt for TARS hit a ceiling of $72.4 million in Q4 2025 and a floor of $19.2 million in Q1 2022.
  • Median Non-Current Debt over the past 4 years was $29.9 million (2023), compared with a mean of $45.0 million.
  • Biggest five-year swings in Non-Current Debt: surged 190.88% in 2024 and later increased 0.77% in 2025.
  • Tarsus Pharmaceuticals' Non-Current Debt stood at $19.4 million in 2022, then skyrocketed by 53.44% to $29.8 million in 2023, then skyrocketed by 140.94% to $71.8 million in 2024, then grew by 0.83% to $72.4 million in 2025.
  • The last three reported values for Non-Current Debt were $72.4 million (Q4 2025), $72.3 million (Q3 2025), and $72.1 million (Q2 2025) per Business Quant data.